"phase 3 study on a life extending Cancer treatment with high likelihood of success"
Yet they could not find a partner or funding? Well funding that wasn't toxic? Pharmas shell out billions for promising drugs but not for slam dunk cancer drug that would have cost them 10-20M?
Uplist is not going to happen way things are. For one they don't even meet MC requirements. With OS likely in 300M+ range within few months how are they going meet min price requirements? There is no way this is going to $1.5 BILLION market cap on pink sheets. They'd have to do another massive reverse split. Price would crash again and they would have trouble meeting MC requirement.
Also they are burning through cash fast. They'll need to raise again. Which will end with this stock where its been last couple months as all old shareholder value will get wiped out again. Just got to hope note holders sell out quick enough and give this some time to bounce without a huge selling ceiling overhead.
Great Post TP, The fact that the IDMC...whom are requested by the FDA to look at the safety data for the treated patients in the trial already did their look and "Recommended to continue without modification" says to me that Positive Phase 3 results are around the corner.
Fact is, that it is the job of the Independent Safety Monitoring Board/Committee to recommend termination of the trials if they see any issues that could cause harm to the patients. Those beyond normal expected and/or accepted side effects.
No significant events says to me that the Efficacy and Pharmacokinetics of the trial vs. standard of care will be a slam dunk seeing as hundreds of procedures have already been conducted in Europe! More than 100 at a single hospital. Approved care in EU will soon be an approved care by the FDA! IMHO LONG DCTH